| Clinical features
CSVD is characterized by insidious onset in most patients, and clinical manifestations vary from non-symptom to lacunar infarction and cognitive dysfunction. The location, extent, and number of lesions are the crucial factors of the presence or severity of the patient's symptoms. Cognitive impairment of CSVD may have a characteristic cognitive decline pattern, that is, typically early involvement in the domains of attention, processing speed, and executive function, and relatively complete memory function. It can progress into mild cognitive impairment and subcortical VaD eventually. 4 Other noncognitive manifestations may accompany, 15 such as gait disorders, emotional and behavioral disorders, bladder dysfunction, and so forth. The recognition of non-cognitive symptoms should be emphasized in the clinical practice when it comes to differential diagnosis.
Collecting vascular factors related to CSVD, stroke symptoms, and onset time, onset form, specific clinical manifestations, disease progression, diagnosis, treatment, and outcome is necessary. Furthermore, the dynamics of the ability of daily living and the relationship between CSVD and cognitive impairment should not be ignored. Moreover, it is still requisite to obtain other medical history to rule out other factors that cause cognitive impairment.
Detailed physical examination of the nervous system should be conducted. Apart from cognitive impairment, sphincter dysfunction, gait abnormalities, and pseudobulbar paralysis are concomitant symptoms often observed in CSVD, although the early signs of their related focal lesions are not so obvious to detect. Enough attention should be paid in the early recognition of the symptoms of non-cognitive impairment, for it may assist dramatically in differential diagnosis.
| Neuropsychological assessment
Neuropsychological assessment can be of great help in the diagnosis and differential diagnosis in cognitive impairment of CSVD, which requires comprehensive cognitive assessment scales. Though executive dysfunction is considered to be the most prominent clinical feature of cognitive impairment of CSVD, there are often damages in memory and other cognitive domains that accompany this condition. Thus, a full-scale cognitive-function evaluation should be carried out.
| General cognitive function screening and evaluation
The Mini-Mental State Examination is a cognitive-function screening scale applied globally. Due to its time saving and easy operation, it is widely used as a primary screening tool in communities and hospitals for the purpose of distinguishing the normal elderly from pa- tests reflecting attention and executive function. It is a good rating instrument for cognitive impairment of CSVD and is worth further promotion and application. 16 The National Institute of Neurological Disorders and Stroke/Canadian Stroke Network (NINDS/CSN) has proposed three sets of neuropsychological assessment of VCI: a 60-minute protocol, a 30-minute protocol, and a 5-minute protocol. 2 All three sets of protocols encompass an assessment of executive function and memory, with a selection of short easy-to-use tests that are designed to be short and easy to evaluate.
| Neuropsychological assessment of each cognitive subphase
In clinical practice, memory assessment mainly focuses on episodic memory, with auditory word-learning tests, the Wechsler Memory Scale, and logical memory tests. 
| Assessment of mental condition and behavior
The 
| Imaging examination
Neuroimaging methods can effectively assist in the clinical identification of neurodegenerative pathology and CSVD in elderly patients with cognitive impairment. At present, MRI is the main imaging evaluation basis.
| Magnetic resonance imaging
Cranial MRI is the most important tool to detect cognitive dysfunc- ischemic white matter damage and lacunar state. 19 The lacunar state is defined as multiple lacunar infarct in deep gray matter (number of lesions >5) combined with moderate or severe white matter injury. The moderate or severe white matter injury includes extensive cap, irregular halo, diffuse fusion of white matter hyperintensity, and extensive white matter changes. 19 Cognitive impairment caused by lacunar infarct and white matter hyperintensity, that is, subcortical VCI, is more common in patients with more than two lacunar infarcts outside the brainstem and those with one or two lacunar infarcts in critical zones accompanied by extensive white matter hyperintensity at the same time. 4 
Cerebral microinfarction
The diameter of cerebral microinfarction is 0.05-3 mm, which cannot be detected by conventional MRI, and sometimes can be detected in high-field-strength MRI. In the acute phase of microinfarction, focus of hyperintensity is observed on DWI while round or ovoid focus of hypointensity is observed on apparent diffusion coefficient imaging.
There was a significant correlation between the number of microinfarctions and the degree of cognitive impairment. 21 The total number of microinfarctions in a brain can reach hundreds to thousands. The quantification of cerebral microinfarction is challenging and the best way to detect cerebral microinfarction is ultra-highfield-strength 7T-MRI. 22 Patients with more than three cerebral microinfarctions display significant cognitive decline in language, visual space, and executive function. 23 
Cerebral microbleed
The typical features of cerebral microbleed (CMB) on MRI are round or ovoid signal loss, of usually 2-5 mm in diameter, which are visible on T2*GRE or SWI sequence and invisible on CT, FLAIR, T1WI, and T2WI sequences. Cerebral amyloid angiopathy (CAA) is the most common cause of cerebral microhemorrhage.
The number of CMBs is an independent predictor of the severity of cognitive impairment, 24 and it has a certain correlation with the location of CMBs. The impact of the type, location, and number of CMBs on cognitive impairment are still under investigation. In a 5.2-year follow-up research involving 2602 subjects, the results showed that three or more CMBs were significantly associated with dementia or VaD regardless of location. 25 
Perivascular space
The imaging features of the perivascular space are fluid-filled space that surrounds the blood vessels and appears linear when imaged parallel to the blood vessels and round or ovoid when imaged perpendicular to the blood vessels. Similar to CSF, the lesions, of usually less than 3 mm in diameter, are of low signal on T1WI and FLAIR and of high signal on T2WI.
There is a certain correlation between enlarged perivascular space and cognitive dysfunction. A 5-year follow-up study based on 2612 elderly people showed that the short axis of round or ovoid signal loss in the subcortical region was more than 3 mm and the incidence of enlarged perivascular space was 16.2%. Enlarged perivascular space more than quadruples the risk of VaD.
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Brain atrophy
Brain atrophy caused by CSVD refers to the decrease of brain volume, excluding the decrease of local volume caused by cerebral infarct. Brain atrophy in CSVD is mainly due to neurodegenerative changes in the distal brain tissue in addition to local tissue damage caused by CSVD. 27 Brain atrophy is a strong predictor of cognitive impairment in patients with CSVD 18 and there is growing evidence that the impact of subcortical ischemic injury on cognitive function is mediated by the following cortical gray matter injury after ischemic injury. 28 
Other imaging markers
In addition to the traditional MRI plain scan, other new imaging markers can give certain guiding value. Diffusion tensor imaging (DTI) is an MRI-based technique aimed at detecting ultrastructural tissue damage by measuring water molecular diffusion. 29 Abnormalities in DTI parameters occur in patients with CSVD and are associated with cognitive impairment and disease progression. 
However, it deserves further investigation to confirm the diagnostic value of the decreased cerebral blood flow in CSVD and its related cognitive impairment.
The results of fluorodeoxyglucose-positron emission tomography (FDG-PET) showed that there were differences in low metabolic patterns between Alzheimer's disease (AD) and VCI. 31 In patients with VCI, FDG-PET showed a decrease in metabolism in the local cortex and some scattered subcortical areas, affecting the subcortical region and sensorimotor cortex to a greater extent than AD. 32 However, the explanation of these results is limited and needs to be studied further.
Recommendations 
| Laboratory examinations
Laboratory examination can also help to find the risk factors of CSVD, and distinguish it from other causes of cognitive impairment, which is helpful to the etiological diagnosis and differential diagnosis of cognitive impairment of CSVD.
| Blood tests
On one hand, to find the risk factors of CSVD, the blood glucose, blood lipid, blood homocysteine, coagulation function, and anticardiolipin antibody should be detected. On the other hand, to exclude other causes of cognitive impairment, the following tests should be performed, including electrolyte testing, liver and kidney function, folic acid, vitamin B12, thyroid function, syphilis, HIV, heavy metals, drug or toxicological testing, tumor markers, paraneoplastic antibodies, immune sets, and so on.
| CSF tests
The levels of Aβ 40 and Aβ 42 in the CSF of most patients with cognitive impairment of CSVD are normal, while the levels of Aβ 40 and Aβ 42 in the CSF of patients with CAA are decreased. The levels of T-tau and P-tau in the CSF are normal in most patients with cognitive impairment of CSVD. 33 In addition, there are several other biomarkers that can assist in differentiating cognitive impairment of CSVD from AD. In patients with cognitive impairment of CSVD, the increased ratio of the CSF/ serum albumin can reflect the breakdown of blood-brain barrier, the changes of matrix metalloproteinases in the CSF can reflect the decomposition of extracellular matrix related to vascular diseases, neurons in the CSF can reflect axonal injury, and inflammatory cytokines and adhesion molecules in blood can reflect inflammatory injury. 34 These markers are not specific but can improve the accuracy of diagnosis for cognitive impairment of CSVD by using these markers alone or in combination. 
| Gene tests
| Diagnostic criteria
At present, according to the guidelines related to VCI, CSVD is diagnosed by etiology or classification. 4, 5 Therefore, in combination with current international guidelines for the diagnosis of cognitive impairment of CSVD, the following factors must be met: (i) the establishment of the presence of cognitive impairment; and (ii) the determination that CSVD is the dominant pathology that accounts for the cognitive deficits. However, there is currently no uniform diagnostic criteria for cognitive impairment of CSVD. Based on the current international guidelines, we propose the diagnostic criteria for cognitive impairment of CSVD as listed in Table 1 .
Recommendations: Detailed medical history collection and neurological examination should be conducted to find evidence of CSVD and its correlation with cognitive impairment, and to exclude other diseases that can cause cognitive impairment.
| TRE ATMENT
| Preventive strategies
Preventive interventions may have a modest effect at the individual level, but lead to a major reduction in the burden at the population level. The preventive interventions mainly include lifestyle modifications, controlling vascular risk factors, treatment of primary vascular diseases, and so on.
| Life factors
Lower levels of education are associated with higher risk of de- 
| Vascular risk factors and associated vascular diseases
The effectiveness of lowering blood pressure to prevent cognitive impairment after stroke in the elderly remains controversial.
However, in view of the benefits of antihypertensive therapy for vascular outcomes, it is recommended to treat hypertension in people with vascular risk factors 3 (level of evidence: IIb).
The level of evidence for treating diabetes and hyperglycemia to reduce the risk of VCI and dementia is quite low. 41 However, the protective effect on multiple target organs is enough to recommend strict glycemic control. Moreover, strict glycemic control can reduce the decrease in cerebral blood volume in diabetic patients 42 (level of evidence: IIb).
In statins trials, which use cognitive assessment as a secondary endpoint, there is no evidence that statins reduce the risk of cognitive decline or dementia. 43 However, these studies were not powered to answer the question because the follow-up period was too short (level of evidence: IIb).
| Cerebral small vessel disease
Few primary or secondary preventive intervention studies have provided cognitive end points. In the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes), 3020 patients with subcortical infarction were enrolled in a multicenter, randomized, controlled, double-blind trial and followed up for 12 months. Compared with the effect of dual antiplatelet therapy versus single aspirin, and intensive blood pressure lowering versus usual targets in patients, dual antiplatelet therapy or intensive antihypertensive therapy had no significant therapeutic effect on cognitive end points 44 (level of evidence: IIb).
TA B L E 1 Diagnostic criteria for cognitive impairment of CSVD
Items Evidence
Cognitive impairment: subjective cognitive decline; objective evidence of cognitive impairment Mild cognitive impairment: (i) cognitive decline in one or more cognitive functional domains; (ii) cognitive impairment is not sufficient to affect life independence.
Dementia or major cognitive disorder: (i) clear and significant deficits in objective assessment based on a validated objective measure of neurocognitive function in two or more cognitive domains; (ii) the cognitive deficits are sufficient to interfere with independence.
Presence of neuroimaging (MRI) evidence of CSVD (one of the following) (i) Multiple lacunar infarctions in white matter and deep gray matter; (ii) ischemic white matter lesions; (iii) enlarged perivascular space; (iv) cortical microinfarction and cerebral microbleed.
Identification of CSVD as evidence of cognitive impairment
Clinical evidence: (i) documented history of CSVD, with cognitive decline temporally associated with the event; (ii) evidence for decline is prominent in speed of information processing, complex attention and/or frontal-executive functioning. One of the following features is additionally present: early gait disorder, early urination control disorder (which cannot be explained by urologic disease), personality and mood changes.
Imaging evidence of CSVD is sufficient to explain the existence of cognitive impairment: (i) multiple lacunar infarcts (>2) outside the brainstem; one to two lacunes may be sufficient if strategically placed or in combination with extensive white matter lesions; (ii) extensive and confluent white matter lesion-extending periventricular and deep white matter lesions: extending caps (>10 mm as measured parallel to ventricle) or irregular halo (>10 mm broad, irregular margins and extending into deep white matter) and diffusely confluent hyperintensities (>25 mm, irregular shape) or extensive white matter change (diffuse hyperintensity without focal lesions), and lacune(s) in the deep grey matter; (iii) enlarged perivascular space: large sample studies were required to provide corresponding evidence; (iv) cortical microinfarction and cerebral microbleed: large sample studies were required to provide corresponding evidence.
Exclusion criteria Exclude other imaging changes or diseases sufficient to explain memory or other cognitive impairment, such as no cortical and/or subcortical non-lacunar infarction, cerebral hemorrhage; specific causes of white matter (multiple sclerosis, sarcoidosis, brain radiotherapy); brain lesions (such as Alzheimer's disease, Lewis dementia, frontotemporal dementia, Parkinson's disease, tumor, hydrocephalus, trauma, syphilis, AIDS, Creutzfeldt-Jakob disease, etc.); serious mental illness and epilepsy, alcohol and drug abuse, metabolic abnormalities, and so forth.
CSVD, cerebral small vessel disease.
| Comprehensive interventions
In the FINGER Trial, 1260 people at high risk of VCI aged 60-77 years were enrolled in the randomized, double-blind, controlled trial and followed up for 2 years. The participants were randomly assigned to a group of comprehensive interventions (reasonable diet, exercise, toms. There were no obvious side-effects or withdrawal reactions. 52 However, the sample size of this study was small, with only 16 cases (level of evidence: III).
| Memantine
Two multicenter, randomized, double-blind, placebo-controlled clinical trials of memantine focused on mild to moderate VaD patients.
The results showed that cognitive function was slightly improved, but the global functioning was not 53, 54 (level of evidence: IIa).
| Dl-3-n-butylphthalidle
Dl-3-n-butylphthalidle (NBP), an anti-VCI drug developed in China, has a protective effect on cognitive impairment in rats with ischemic brain injury. NBP is not only for ischemic stroke: it has also been reported to increase the expression of NR2B and synaptophysin in the hippocampus of aged rats after chronic cerebral hypoperfusion and to increase brain acetylcholine level.
In a randomized, double-blind, placebo-controlled trial, Jia et al. 
| Cytidinediphosphocholine
A meta-analysis including 14 randomized, controlled, double-blind clinical trials was conducted to evaluate the efficacy of cytidinediphosphocholine in the treatment of 1051 patients with memory impairment (VCI or AD). The results showed that citicoline could improve memory, behavior, and overall cognitive function in elderly patients with cognitive impairment (VCI or AD 56 ; level of evidence: IIb).
| Ginkgo biloba extract
A randomized, double-blind, placebo-controlled trial of ginkgo biloba extract was conducted to determine its efficacy and safety in 90 VCI patients for 6 months. The results showed that ginkgo biloba extract could delay the decline of cognitive function in patients with VCI, 57 but its efficacy and safety still need to be confirmed by further studies (level of evidence: IIb).
| Nimodipine
A randomized, double-blind, placebo-controlled clinical trial has shown that nimodipine could improve neuropsychological function. 58 However, the sample size of this study was small, with only 45 treated cases (level of evidence: III). 
